KTN3379, a human anti- HER3 mAb, was recently shown to significantly suppress tumor growth in HNSCC xenograft models and inhibit activations of HER3, EGFR, AKT and ERK in vivo when combined with cetuximab34. Here, ERBB3 is linked to neoplasm.